A prolonged course of antibiotic therapy dramatically reduces the risk of recurrence in patients with renal cyst infections in the context of autosomal dominant polycystic kidney disease (ADPKD), a ...

Polycystic kidney disease (PKD) is an intractable disorder that causes fluid-filled cysts to grow in the kidneys. It is typically seen in adults. As one of the most prevalent hereditary kidney ...

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function. The disease affects more than 12 ...

A compound originally developed as a cancer treatment may hold promise for treating polycystic kidney disease (ADPKD), which affects more than half a million Americans and can lead to kidney ...

Please provide your email address to receive an email when new articles are posted on . The study reported elevated adjusted rates for four non-pulmonary complications in those with vs. without cystic ...

Researchers have reduced the formation and growth of kidney cysts in autosomal dominant polycystic kidney disease (ADPKD) models by blocking the binding of a microRNA called miR-17 to the PKD1 and ...

Vertex Pharmaceuticals is set to build upon its success cystic fibrosis (CF) and its potential blockbuster Casgevy through its non-opioid pain and renal therapy pipelines, says CEO Reshma Kewalramani.

Chronic kidney disease (CKD) is a public health challenge that affects more than 800 million people worldwide. 1 CKD can be caused by a variety of disease processes. Many causes are difficult to ...